Pfizer And Sanofi China GMs Disagree On Commercial Models – PharmAsia Summit Shanghai
This article was originally published in PharmAsia News
Pfizer Inc.’s Wu Xiaobing and Sanofi China’s Fabrice Baschiera discuss how their companies are creating value for patients and payers in China during a keynote panel during the PharmAsia Summit in Shanghai.
You may also be interested in...
Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.
Taiwan Liposome Co. Ltd. has the funds and team to reach outside of its base in Taiwan to turn old drugs into new products and is looking for opportunities at Asia-specific product applications.
Generon in Shanghai was founded by former Hutchison MediPharma employees to target a niche market between expensive import drugs and lower quality domestic products.